Coumarin analog compounds for safer anticoagulant treatment

Details Coumarin analog compounds for safer anticoagulant treatment Coumarin analog compounds for safer anticoagulant treatment

2007-02-20

2008-10-21

Dentz, B. (Department: 1625)

Chemistry: analytical and immunological testing

Biospecific ligand binding assay

C514S457000, C549S285000

Reexamination Certificate

active

07439077

ABSTRACT:
The present invention relates to the albumin-guided development of coumarin analogs and the analogs developed thereby. The coumarin analogs of the present invention are identified and isolated by the fact that they have binding sites to albumin which are different than the binding sites of conventional coumarin analogs such as sodium warfarin, and as a result will be less prone to be displaced since the binding site of sodium warfarin is shared by numerous drugs such as aspirin. The coumarin analogs of the invention are advantageous because they can achieve the effects of the prior coumarin analogs with a minimum of metabolic complications and undesirable side effects.

Affiliated with

Also associated with

Rating

Coumarin analog compounds for safer anticoagulant treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Coumarin analog compounds for safer anticoagulant treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Coumarin analog compounds for safer anticoagulant treatment will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4014422